For immediate release:

Seinäjoki, Finland 28.02.2025

Eevia Health Plc’s ("Eevia" or the "Company") rights issue has now been registered by Euroclear Sweden. The Company hereby announces that the last day of trading in BTA (paid subscribed share) is March 5, 2025, and the cut-off date is March 7, 2025. The paid subscribed shares will be replaced by ordinary shares which are expected to be booked into the respective custodian/VP account on March 11, 2025. The registration with the Finnish Trade Register has not been completed yet, and a delay in registration could delay the delivery of shares to custodian/VP accounts.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc

Email: stein.ulve@eeviahealth.com

Telephone: +358 400 22 5967

Information about Eevia Health Plc

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.